Summaries for patients. Preventing bone loss in men with prostate cancer.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000008:administration & dosage* / Q000009:adverse effects; D000726:Androgen Antagonists / Q000009:adverse effects*; D015415:Biomarkers / Q000378:metabolism; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001862:Bone Resorption / Q000139:chemically induced / Q000517:prevention & control*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D006615:Hip; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012307:Risk Factors; D013131:Spine / Q000378:metabolism
D000726:Androgen Antagonists; D015415:Biomarkers; D050071:Bone Density Conservation Agents; D019386:Alendronate